E
Eikon Therapeutics
Pioneering a new method of drug discovery based on tracking and measuring movement of individual proteins in live cells
At a glance
- Founded
- 2019
- Headquarters
- Hayward, United States
- Listing
- IPO 2026
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Eikon Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A3 investors entered at this stage
Innovation Endeavors- TGThe Column Group
Foresite Capital
Series B and later20 investors entered at this stage
- HGHarel Group
- TIThe Howard Hughes Medical Institute
General Catalyst
CPP Investments- SMSoros Fund Management
- AIAlexandria Venture Investments
- EVE15 VC
Horizons Ventures- UIUC Investments
- AAAbu Dhabi Investment Authority
- HEHartford HealthCare Endowment
- ECEcoR1 Capital
- JAJanelia
AME Cloud Ventures
StepStone Group- SMSoros Capital Management
- SCSchroders
T. Rowe Price- UCUniversity of California
- BEBerkeley
Ownership
Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (May/2026).
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
58 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Eikon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eikon Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.